ArticleCerebellum (London, England)2026
Expanding the Spectrum of AFG3L2 Mutations: A Case with Late-Onset Autosomal Recessive Spinocerebellar Ataxia from Iran.
Article in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spastic ataxia type 5 (SPAX5) is a rare autosomal-recessive neurodegenerative disorder caused by AFG3L2 mutations affecting the mitochondrial m-AAA protease complex. previously reported cases presented in early childhood with seizures and developmental delay. We report a 38-year-old woman with progressive gait ataxia, dystonia, dysmetria, scanning speech, and hyperreflexia. Brain MRI revealed cerebellar atrophy, while metabolic studies were normal. Genetic testing identified a homozygous AFG3L2 variant (c.2176G > T; p.Val726Phe) consistent with SPAX5. Family history included two mildly affected children. Unlike previously described early-onset SPAX5 cases, this patient exhibited adult-onset, slowly progressive symptoms without seizures or cognitive delay, suggesting partial preservation of protease activity. The p.Val726Phe substitution may retain residual function, accounting for the milder phenotype. This case, the first genetically confirmed SPAX5 from Iran, expands the clinical spectrum of AFG3L2-related disorders and emphasizes considering this diagnosis in adult-onset ataxia.
Indexed as
Identifiers
41922636What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.